24 mg
Zofran is a brand name for the drug ondansetron, prescribed to treat or prevent nausea and vomiting. Doctors sometimes prescribe Zofran to treat nausea and vomiting caused by cancer treatments such as chemotherapy and radiation therapy. Zofran also can treat nausea and vomiting after surgery. 1 For radiation therapy, a typical adult dose of Zofran is 24 mg daily. 2  For prevention of nausea and vomiting after surgery, a typical adult dose of Zofran is 16 mg before surgery. All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients. • 73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m 2 intravenous together with 2 to 4 mg dexamethasone orally. • 71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy. For pediatric patients 4 through 11 years of age, the dosage is one 4-mg ZOFRAN Tablet or one 4-mg ZOFRAN ODT Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of ZOFRAN Oral Solution given 3 times a day. ZOFRAN Tablets, 8 mg (ondansetron HCl dihydrate equivalent to 8 mg of ondansetron), are yellow, oval, film-coated tablets engraved with “Zofran” on one side and “8” on the other in daily unit dose packs of 3 tablets (NDC 0173-0447-04), and bottles of 30 tablets (NDC 0173-0447-00). 1 However, no single intravenous dose of ondansetron should exceed 16 mg due to the risk of QT prolongation. 2  The new information does not change any of the recommended oral dosing regimens for ondansetron, including the single oral dose of 24 mg for chemotherapy induced nausea and vomiting. RECOMMENDATION: The new information on QT prolongation does not change any of the recommended oral dosing regimens for ondansetron. It also does not change the recommended lower dose intravenous dosing of ondansetron to prevent post-operative Adults. The recommended adult intravenous dosage of ZOFRAN is three 0.15-mg/kg doses up to a maximum of 16 mg per dose [see CLINICAL PHARMACOLOGY ]. The first dose is infused over 15 minutes beginning 30 minutes before the start of emetogenic chemotherapy. The first dose is to be administered 30 minutes before the start of moderately to highly emetogenic chemotherapy. Subsequent doses (0.15 mg/kg up to a maximum of 16 mg per dose) are administered 4 and 8 hours after the first dose of ZOFRAN. The updated label will state that ondansetron can continue to be used in adults and children with chemotherapy-induced nausea and vomiting at the lower intravenous dose recommended in the drug label, a dose of 0.15 mg/kg administered every 4 hours for three doses; however, no single intravenous dose should exceed 16 mg. RECOMMENDATION: The new information on QT prolongation does not change any of the recommended oral dosing regimens for ondansetron. It also does not change the recommended lower dose intravenous dosing of ondansetron to prevent post-operative nausea and vomiting. Postoperative Nausea and Vomiting. The recommended dosage is 16 mg given as two 8-mg ZOFRAN Tablets or two 8-mg ZOFRAN ODT Tablets or 20 mL (4 teaspoonfuls equivalent to 16 mg of ondansetron) of ZOFRAN Oral Solution 1 hour before induction of anesthesia. ZOFRAN Tablets, 8 mg (ondansetron HCl dihydrate equivalent to 8 mg of ondansetron), are yellow, oval, film-coated tablets engraved with “Zofran” on one side and “8” on the other in daily unit dose packs of 3 tablets (NDC 0173-0447-04), and bottles of 30 tablets (NDC 0173-0447-00). The recommended adult oral dosage of ZOFRAN is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin ≥ 50 mg/m. ZOFRAN Tablets, 8 mg (ondansetron HCl dihydrate equivalent to 8 mg of ondansetron), are yellow, oval, film-coated tablets engraved with “Zofran” on one side and “8” on the other in daily unit dose packs of 3 tablets (NDC 0173-0447-04), and bottles of 30 tablets (NDC 0173-0447-00).
http://www.everydayhealth.com/drugs/ondansetron http://www.medicines.org.uk/emc/medicine/17650/SPC/ http://www.rxlist.com/zofran-drug/indications-dosage.htm http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm http://www.rxlist.com/zofran-injection-drug/indications-dosage.htm http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm310219.htm http://www.rxlist.com/zofran-drug/indications-dosage.htm http://www.rxlist.com/zofran-drug/indications-dosage.htm
recommended dose for ondansetron